Literature DB >> 21792088

Pancreatic cancer alters human CD4+ T lymphocyte function: a piece in the immune evasion puzzle.

Paola Fogar1, Daniela Basso, Elisa Fadi, Eliana Greco, Giorgia Pantano, Andrea Padoan, Dania Bozzato, Monica Facco, Maria Colomba Sanzari, Sara Teolato, Carlo-Federico Zambon, Filippo Navaglia, Gianpietro Semenzato, Sergio Pedrazzoli, Mario Plebani.   

Abstract

OBJECTIVES: To verify whether the dysregulation of CD4 T cells concurs in worsening the outcome of pancreatic cancer, we compared the effects of pancreatic cancer and other gastrointestinal cancer cell-conditioned media on the (1) proliferation, migration, and differentiation of CD4 T cells and (2) expansion of CD4 memory (CD45RO), naive (CD45RA), activated (CD69), and regulatory (CD25) subsets.
METHODS: After culture of CD4 T cells in control, pancreatic (BxPC3, Capan1, MiaPaCa2), or gastrointestinal cancer (AGS, HepG2, HT29) cell-conditioned media, we evaluated proliferation, migration, interferon γ (IFNγ) production, and CD45RA, CD45RO, CD69, and CD25 membrane expression in control and conditioned CD4 T cells.
RESULTS: Only pancreatic cancer-conditioned media (1) inhibited CD4 T-cell proliferation (P < 0.001) and migration under human stromal cell-derived factor-α chemotaxis (P < 0.001) and (2) induced CD4 T-cell IFNγ production (P < 0.05) and the expansion of the CD69-positive subset (P < 0.001) with respect to the control, with no changes being found in the CD45RA, CD45RO, and CD25 subsets.
CONCLUSIONS: The in vitro findings achieved in the present study demonstrate that pancreatic cancer cells inhibit CD4 T-cell proliferation and migration, induce IFNγ production, and favor a CD69 subset expansion, suggesting that CD4 T cells play an important role in pancreatic cancer immune evasion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21792088     DOI: 10.1097/MPA.0b013e31822077b8

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  14 in total

1.  CD4+ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4+ T cells in pancreatic cancer development.

Authors:  Lisa Goebel; Evelin Grage-Griebenow; Artur Gorys; Ole Helm; Geeske Genrich; Lennart Lenk; Daniela Wesch; Hendrik Ungefroren; Sandra Freitag-Wolf; Bence Sipos; Christoph Röcken; Heiner Schäfer; Susanne Sebens
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

2.  Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study.

Authors:  Ying Qiu; Mark M Yun; Ming Bao Xu; Yi Zhong Wang; Sheng Yun
Journal:  Int J Clin Oncol       Date:  2012-07-31       Impact factor: 3.402

Review 3.  Complex role for the immune system in initiation and progression of pancreatic cancer.

Authors:  Kristin S Inman; Amanda A Francis; Nicole R Murray
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

4.  L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression.

Authors:  Evelin Grage-Griebenow; Elfi Jerg; Artur Gorys; Daniel Wicklein; Daniela Wesch; Sandra Freitag-Wolf; Lisa Goebel; Ilka Vogel; Thomas Becker; Michael Ebsen; Christoph Röcken; Peter Altevogt; Udo Schumacher; Heiner Schäfer; Susanne Sebens
Journal:  Mol Oncol       Date:  2014-04-02       Impact factor: 6.603

5.  Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression.

Authors:  Lisa D Mills; Lizhi Zhang; Ronald Marler; Phyllis Svingen; Maite G Fernandez-Barrena; Maneesh Dave; William Bamlet; Robert R McWilliams; Gloria M Petersen; William Faubion; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157

Review 6.  Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.

Authors:  Divya Murthy; Kuldeep S Attri; Pankaj K Singh
Journal:  Front Physiol       Date:  2018-04-04       Impact factor: 4.566

7.  The clinical implication of CD45RA+ naïve T cells and CD45RO+ memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction.

Authors:  Junjie Hang; Junjie Huang; Siyuan Zhou; Lixia Wu; Yingwei Zhu; Lina Zhu; Hanyu Zhou; Kequn Xu; Hua Jiang; Xuguang Yang
Journal:  Cancer Med       Date:  2019-02-14       Impact factor: 4.452

8.  Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study.

Authors:  Daniela Basso; Paola Fogar; Massimo Falconi; Elisa Fadi; Cosimo Sperti; Chiara Frasson; Eliana Greco; Domenico Tamburrino; Sara Teolato; Stefania Moz; Dania Bozzato; Michela Pelloso; Andrea Padoan; Giuseppe De Franchis; Elisa Gnatta; Monica Facco; Carlo-Federico Zambon; Filippo Navaglia; Claudio Pasquali; Giuseppe Basso; Gianpietro Semenzato; Sergio Pedrazzoli; Paolo Pederzoli; Mario Plebani
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

9.  SMAD4 loss enables EGF, TGFβ1 and S100A8/A9 induced activation of critical pathways to invasion in human pancreatic adenocarcinoma cells.

Authors:  Stefania Moz; Daniela Basso; Dania Bozzato; Paola Galozzi; Filippo Navaglia; Ola H Negm; Giorgio Arrigoni; Carlo-Federico Zambon; Andrea Padoan; Paddy Tighe; Ian Todd; Cinzia Franchin; Sergio Pedrazzoli; Leonardo Punzi; Mario Plebani
Journal:  Oncotarget       Date:  2016-10-25

Review 10.  Role of immune cells in pancreatic cancer from bench to clinical application: An updated review.

Authors:  Jae Hyuck Chang; Yongjian Jiang; Venu G Pillarisetty
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.